ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX): 53 pipeline candidates · 7 upcoming catalysts · ~16 mo cash runway · 37 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.7 months
D/E -1.74 · 0% dilution
Lead: Approved
53 candidates
7 upcoming, next in ~18d
0 buys · 9 sells (180d)
A transparent, data-derived signal for ImmunityBio, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.3B
Cash
$205.2M
Quarterly Burn
$75.4M
Runway
15.7 mo
Revenue
$44.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (53 candidates)
| Drug | Phase |
|---|---|
| 10-1074 | Phase 1 |
| AAHI-SC2 Vaccine | Phase 1 |
| AAHI-SC3 Vaccine | Phase 1 |
| ABRAXANE | Approved |
| agent-797 | Phase 3 |
| allogeneic invariant natural killer t cells | Phase 2 |
| ALT-803 | Phase 2 |
| aNK | Phase 3 |
| Anktiva | Phase 2 |
| BCG | Phase 1/Phase 2 |
Showing 10 of 53 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
393
Total value held
$1.61B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 30,255,428 | $232.1M |
| blackrock, inc. | 26,346,443 | $202.1M |
| state street corp | 17,708,103 | $135.8M |
| vanguard portfolio management llc | 16,322,844 | $125.2M |
| d. e. shaw & co., inc. | 12,571,597 | $96.4M |
| susquehanna international group, llp | 8,696,276 | $66.7M |
| geode capital management, llc | 8,031,921 | $61.6M |
| citadel advisors llc | 5,135,878 | $39.4M |
| two sigma investments, lp | 4,385,500 | $33.6M |
| lmr partners llp | 4,338,800 | $33.3M |
Showing top 10 of 393 institutional holders of ImmunityBio, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ImmunityBio, Inc.'s pipeline?
ImmunityBio, Inc. (IBRX) has 53 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ImmunityBio, Inc.'s lead drug candidate?
ImmunityBio, Inc.'s most advanced tracked candidate is 10-1074 (Phase 1) for HIV Infection.
What is ImmunityBio, Inc.'s next catalyst?
ImmunityBio, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combinatio" — expected July 6, 2026.
What is ImmunityBio, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ImmunityBio, Inc. has approximately 15.7 months of cash runway.
What is ImmunityBio, Inc.'s market capitalization?
ImmunityBio, Inc.'s market capitalization is approximately $7.3B.
Get the full picture on ImmunityBio, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.